Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859291 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3868197 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3863209 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL313504 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL1475879 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL61256 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9209758 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3989043 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9681594 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3856545 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117128-A1 | INTRAOCULAR PRESSURE LOWERING AGENT, AND AGENT FOR TREATING OR PREVENTING GLAUCOMA OR OCULAR HYPERTENSION | ＳＡＮＳＨＯ株式会社 | 2024-06-06 | — | — | WO | disclosed |
| CN-116710105-A | Therapeutic agent for pulmonary fibrosis | 山椒株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-20230108750-A1 | CARBALYSOPHOSPHATIDIC ACID | OCHANOMIZU UNIVERSITY (JP) | 2023-04-06 | — | — | US | disclosed |
| US-10413559-B2 | Method for treating demyelinating disease | OCHANOMIZU UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
| EP-2949329-B1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | UNIV OCHANOMIZU (JP) | 2019-05-01 | — | — | EP | disclosed |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | OCHANOMIZU UNIVERSITY (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2949329-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | Ochanomizu University (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-5753649-A | Therapeutic agent for osteoporosis and diazepine compound | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5593988-A | DIAZIPINE DERIVATIVES OF THIOPHENE FOR BONE DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0638560-A1 | REMEDY FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108750-A1 | CARBALYSOPHOSPHATIDIC ACID | PHOSPHO1, SGMS1, PLD1 | PTPN7 2293/4885HMGCR 1411/4885RECQL 3592/4885 |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | PMP22, MAG, SGMS1 | PTPN7 1215/4885HMGCR 2093/4885RECQL 3199/4885 |
| US-10413559-B2 | Method for treating demyelinating disease | PMP22, MAG, SGMS1 | PTPN7 1364/4885HMGCR 685/4885RECQL 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.